BullBD Old Apps Site
Home
Details Chart Today news Share news Top gainer Top Looser Upcoming events
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 1 2 3 4 5 6 7 8 9 All
Bank Cement Ceramics Sector Corporate Bond Engineering Financial Institutions Food & Allied Fuel & Power IT Sector Insurance Jute Life Insurance Miscellaneous Mutual Funds Paper & Printing Pharmaceuticals & Chemicals Services & Real Estate Tannery Industries Telecommunication Textile Travel & Leisure All
  • Details
  • Chart
  • News

SQURPHARMA

All Eps Dividend Board Agm Q1 Q2 Q3

SQURPHARMA 24-Oct-2021

(Continuation news of SQURPHARMA): The Company has also reported Consolidated EPS of Tk. 17.99, Consolidated NAV per share of Tk. 102.54 and Consolidated NOCFPS of Tk. 12.43 for the year ended on June 30, 2021 as against Tk. 15.07, Tk. 87.28 and Tk. 12.14 respectively for the same period of the previous year. (end)

SQURPHARMA 06-May-2021

(Continuation news of SQURPHARMA): and Consolidated NOCFPS: Consolidated NAV per share is increased due to incremental Net Profit in comparing to the reporting period ended on March 31, 2020. Consolidated EPS increased due to positive revenue. Consolidated NOCFPS decreased due to higher investment on working capital and higher advance tax payment to facilitate revenue growth in comparing to the same reporting period of previous year. (end)

SQURPHARMA 06-May-2021

(Q3 Un-audited): Consolidated EPS was Tk. 4.36 for January-March 2021 as against Tk. 4.08 for January-March 2020; Consolidated EPS was Tk. 13.12 for July 2020-March 2021 as against Tk. 11.85 for July 2019-March 2020. Consolidated NOCFPS was Tk. 9.40 for July 2020-March 2021 as against Tk. 9.64 for July 2019-March 2020. Consolidated NAV per share was Tk. 96.43 as on March 31, 2021 and Tk. 87.28 as on June 30, 2020. Reason for Significant deviation in Consolidated NAV per share, Consolidated EPS (cont.)

SQURPHARMA 31-Jan-2021

(Q2 Un-audited): The Company has further informed that Consolidated EPS was Tk. 4.33 instead of 4.18 for October-December 2020 as against Tk. 3.98 instead of Tk. 3.70 for October-December 2019. All other information will remain unchanged.

SQURPHARMA 31-Jan-2021

(Q2 Un-audited): Consolidated EPS was Tk. 4.18 for October-December 2020 as against Tk. 3.70 for October-December 2019; Consolidated EPS was Tk. 8.76 for July-December 2020 as against Tk. 7.77 for July-December 2019. Consolidated NOCFPS was Tk. 7.28 for July-December 2020 as against Tk. 5.60 for July-December 2019. Consolidated NAV per share was Tk. 92.47 as on December 31, 2020 and Tk. 87.28 as on June 30, 2020.

SQURPHARMA 12-Nov-2020

(Q1 Un-audited): Consolidated EPS was Tk. 4.66 for July-September 2020 as against Tk. 3.97 for July-September 2019; Consolidated NOCFPS was Tk. 3.47 for July-September 2020 as against Tk. 3.87 for July-September 2019. Consolidated NAV per share was Tk. 97.13 as on September 30, 2020 and Tk. 91.57 as on June 30, 2020.

SQURPHARMA 25-Oct-2020

(Continuation news of SQURPHARMA): The Company has also reported Consolidated EPS of Tk. 15.82, Consolidated NAV per share of Tk. 91.57 and Consolidated NOCFPS of Tk. 12.75 for the year ended on June 30, 2020 as against Tk. 14.98, Tk. 80.40 and Tk. 14.68 respectively for the same period of the previous year. The Company also informed that i) Bonus shares has been recommended in view to utilize its retained amount as capital for business expansion. (cont.2)

SQURPHARMA 09-Jun-2020

(Q3 Un-audited): Consolidated EPS was Tk. 4.28 for January-March 2020 as against Tk. 3.69 for January-March 2019; Consolidated EPS was Tk. 12.44 for July 2019-March 2020 as against Tk. 11.15 for July 2018-March 2019. Consolidated NOCFPS was Tk. 10.13 for July 2019-March 2020 as against Tk. 10.57 for July 2018-March 2019. Consolidated NAV per share was Tk. 88.19 as on March 31, 2020 and Tk. 80.40 as on June 30, 2019.

SQURPHARMA 29-Jan-2020

(Q2 Un-audited): Consolidated EPS was Tk. 4.18 for October-December 2019 as against Tk. 3.70 for October-December 2018; Consolidated EPS was Tk. 8.16 for July-December 2019 as against Tk. 7.46 for July-December 2018. Consolidated NOCFPS was Tk. 5.88 for July-December 2019 as against Tk. 6.83 for July-December 2018. Consolidated NAV per share was Tk. 84.12 as on December 31, 2019 and Tk. 80.40 as on June 30, 2019.

SQURPHARMA 14-Nov-2019

(Q1 Un-audited): Consolidated EPS was Tk. 4.25 for July-September 2019 as against Tk. 4.02 for July-September 2018; Consolidated NOCFPS was Tk. 4.14 for July-September 2019 as against Tk. 4.06 for July-September 2018. Consolidated NAV per share was Tk. 90.00 as on September 30, 2019 and Tk. 86.03 as on June 30, 2019.

Previous Next page